NCT01964495

Reduction of Antibiotic Therapy by Biomakers in Patients With CAP Episodes (REDUCE Study)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 468 (actual)
• Sponsor: Medical Center Alkmaar · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate two different treatment strategies in patients admitted to hospital with Community Acquired Pneumonia. The investigators hypothesize treatment according to both procalcitonin (PCT) and C-reactive protein (CRP) will be effective in reducing the length of antibiotic treatment.

Conditions

• Community Acquired Pneumonia

Interventions

Type	Name	Description
DRUG	Discontinuation of treatment according to CRP levels	The cutoff point is a CRP below 100 mg/L and a reduction to 50% of the initial value.
DRUG	Discontinuation of treatment according to PCT levels	The cutoff point is a PCT below 0.25 mcg/L or a reduction to 10% of the initial value.
DRUG	Treatment according to current guidelines	Often a 7 days course of antibiotics, treatment may be extended if the attending physician deems it necessary.

Timeline

• Start date: 2013-12-05
• Primary completion: 2017-01-20
• Completion: 2017-01-20
• First posted: 2013-10-17
• Last updated: 2022-04-05

Locations

3 sites across 1 country: Netherlands